<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
Amendment No. 1
UNDER THE SECURITIES EXCHANGE ACT OF 1934
WEBMD CORPORATION
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.0001 Par Value
--------------------------------------------------------------------------------
(Title of Class of Securities)
422209106
--------------------------------------------------------------------------------
(CUSIP Number)
Donald F. Parman, SmithKline Beecham Corporation
One Franklin Plaza, Philadelphia, PA 19102
Telephone 215-751-7633
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
November 12, 1999
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
This Amendment No. 1 amends and supplements the Statement of Schedule 13D
electronically filed with the Securities and Exchange Commission (the
"Commission") on February 19, 1999 (the "Initial Statement"). Since the
reporting person now holds less than 5% with this filing, further reporting
under Schedule 13D is no long required.
The undersigned hereby amends and supplements Item 5 of the Initial Statement to
include the following information (capitalized terms used herein without
definition shall have the same meaning as set forth in the Initial Statement).
<PAGE> 2
SCHEDULE 13D
CUSIP NO. PAGE 2 OF 4 PAGES
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SmithKline Beecham Corporation
23-1099050
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Pennsylvania
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 5,351,003
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
5,351,003
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,351,003
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.4%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 3
PAGE 3 OF 4 PAGES
Item 1. Security and Issuer.
Item 2. Identity and Background.
Item 3. Source and Amount of Funds or Other Consideration.
Item 4. Purpose of Transaction.
Item 5. Interest in Securities of the Issuer.
(a) Amount and Percent Beneficially Owned
<TABLE>
<CAPTION>
Registered Name No. of Shares Percent
<S> <C> <C>
SBCorp 5,351,003 2.4%
</TABLE>
(b) Reporting Person has sole power to vote and to dispose of all
of the shares of Common Stock identified in subparagraph (a) above.
(c) Subsequent to Healtheon / WebMD merger, Reporting Person sold
900,000 shares of Common stock in the open market in the following manner:
<TABLE>
<CAPTION>
Transaction Date No. of Shares Price Per Share
<S> <C> <C>
12/10/99 62,500 $43.255
12/13/99 70,000 $41.825
12/13/99 50,000 $41.80
12/13/99 7,500 $41.925
12/13/99 10,000 $42.00
12/15/99 7,500 $40.25
12/17/99 98,000 $39.50
12/17/99 25,000 $39.5625
12/17/99 20,000 $40.00
12/17/99 7,500 $40.0625
12/17/99 2,500 $40.125
12/17/99 10,000 $40.375
12/17/99 5,000 $40.50
12/17/99 2,000 $40.5625
12/20/99 2,000 $39.75
12/20/99 10,000 $39.25
12/20/99 20,500 $39.1875
12/21/99 90,000 $37.00
12/28/99 50,000 $38.8125
12/28/99 50,000 $38.9375
12/28/99 100,000 $39.00
12/28/99 25,000 $39.125
12/28/99 95,000 $39.25
12/28/99 25,000 $39.3125
12/28/99 25,000 $39.4375
12/28/99 25,000 $39.50
12/28/99 5,000 $39.5625
</TABLE>
<PAGE> 4
PAGE 4 OF 4 PAGES
Dr. Tadataka Yamada was granted stock options as a Director of Issuer. Reporting
Person hereby disclaims beneficial ownership of these securities. Reporting
Person's percentage ownership of Issuer has been substantially reduced by
subsequent issue of shares by the Issuer to other third parties.
Item 6. Contracts, Arrangements, Understandings or Relationship With
respect to Securities of the Issuer.
Item 7. Materials to be Filed as Exhibits.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, the undersigned certifies that the information set forth in the
Statement is true, correct and complete.
SMITHKLINE BEECHAM CORPORATION
By: /s/
Donald F. Parman
Secretary
DATED: October 11, 2000
